Roche News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

25.05.22	Roche’s Polivy combination approved by European Commission for people with previously untreated diffuse large B-cell lymphoma (GlobeNewswire)
25.05.22	Roche entwickelt einzigartige PCR-Tests zur Erkennung des Affenpockenvirus (GlobeNewswire)
25.05.22	Roche develops unique PCR tests to detect the monkeypox virus (GlobeNewswire)
24.05.22	Data at the 2022 ASCO Annual Meeting highlight Roche’s continued commitment to innovation in oncology and personalised healthcare (GlobeNewswire)
12.05.22	Roche enters partnership with the Global Fund to support low- and middle-income countries in strengthening critical diagnostics infrastructure (GlobeNewswire)
11.05.22	[Ad hoc announcement pursuant to Art. 53 LR] Roche reports interim results for phase III SKYSCRAPER-01 study in PD-L1-high metastatic non-small cell lung cancer (GlobeNewswire)
10.05.22	Roche pledges to extend commitment to the World Federation of Hemophilia Humanitarian Aid Program to 2028 (GlobeNewswire)
29.04.22	New three-year data for Roche’s Evrysdi (risdiplam) show long-term improvements in survival and motor milestones in babies with Type 1 spinal muscular atrophy (SMA) (GlobeNewswire)
25.04.22	[Ad-hoc-Mitteilung gemäss Art. 53 KR] Roche mit gutem Verkaufswachstum im ersten Quartal 2022 (GlobeNewswire)
22.04.22	CHMP recommends EU approval of Roche’s Tecentriq as adjuvant treatment for a subset of people with early-stage non-small cell lung cancer (GlobeNewswire)
22.04.22	CHMP recommends EU conditional approval of Roche’s potential first-in-class bispecific antibody mosunetuzumab for people with relapsed or refractory follicular lymphoma (GlobeNewswire)
04.04.22	U.S. FDA grants priority review to Roche’s Actemra/RoActemra for the treatment of COVID-19 in hospitalised adults (GlobeNewswire)
04.04.22	New data for Roche’s OCREVUS (ocrelizumab) show benefit in disability progression and cognitive decline in both secondary progressive and primary progressive multiple sclerosis (GlobeNewswire)
30.03.22	Ad hoc announcement pursuant to Art. 53 LR Roche provides update on phase III SKYSCRAPER-02 study in extensive-stage small cell lung cancer (GlobeNewswire)
25.03.22	CHMP recommends EU approval of Roche’s Polivy combination for people with previously untreated diffuse large B-cell lymphoma (GlobeNewswire)
25.03.22	Roche to present data across broad and impactful neuroscience portfolio at 2022 AAN Annual Meeting (GlobeNewswire)
23.03.22	Roche donates additional medicines and diagnostics for Ukraine (GlobeNewswire)
16.03.22	Roche provides molecular testing solutions to identify and differentiate SARS-CoV-2 Omicron variants of concern (GlobeNewswire)
16.03.22	New data for Roche’s Evrysdi (risdiplam) demonstrate long-term efficacy and safety in a broad population of people with spinal muscular atrophy (SMA) (GlobeNewswire)
15.03.22	Roche Generalversammlung 2022 (GlobeNewswire)
15.03.22	Roche Annual General Meeting 2022 (GlobeNewswire)
08.03.22	Roche to present new Evrysdi data at MDA 2022 and highlight expanding neuromuscular disease portfolio (GlobeNewswire)
02.03.22	Roche announces donation of essential medicines to Ukraine (GlobeNewswire)
11.02.22	WHO grants prequalification of Actemra/RoActemra for patients with severe or critical COVID-19 (GlobeNewswire)
11.02.22	New two-year data for Roche’s Vabysmo and Susvimo reinforce potential to maintain vision with fewer treatments for people with two leading causes of vision loss (GlobeNewswire)
03.02.22	[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results in 2021 (GlobeNewswire)
03.02.22	[Ad hoc-Mitteilung gemäss Art. 53 KR] Roche mit gutem Jahresergebnis 2021 (GlobeNewswire)
01.02.22	Changes to the Roche Board of Directors and the Corporate Executive Committee (GlobeNewswire)
01.02.22	Wechsel im Verwaltungsrat und in der Konzernleitung von Roche (GlobeNewswire)
31.01.22	FDA approves Roche’s Vabysmo, the first bispecific antibody for the eye, to treat two leading causes of vision loss (GlobeNewswire)
25.01.22	Roche’s Evrysdi (risdiplam) granted FDA priority review for treatment of pre-symptomatic babies under 2 months of age with spinal muscular atrophy (SMA) (GlobeNewswire)
24.01.22	The Lancet publishes studies showing Roche’s faricimab improved and maintained vision in two leading causes of vision loss, extending time between treatments up to four months (GlobeNewswire)
12.01.22	Roche launches the cobas® pulse system, an industry first professional blood glucose management solution with mobile digital health capabilities to improve patient care (GlobeNewswire)
11.01.22	Roche introduces cobas infinity edge, a new open digital ecosystem for point of care professionals, driving improved patient outcomes and operational efficiencies in healthcare (GlobeNewswire)
24.12.21	Roche COVID-19 At-Home Test granted FDA Emergency Use Authorization to expand access to rapid self-testing solutions in the United States (GlobeNewswire)
14.12.21	Roche’s Polivy combination reduced the risk of disease worsening or death by 27% in people with previously untreated aggressive form of lymphoma (GlobeNewswire)
13.12.21	Roche launches the AVENIO Edge System to simplify and automate next-generation sequencing sample preparation, reduce human error and advance precision medicine (GlobeNewswire)
13.12.21	Interim data from phase III HAVEN 6 study demonstrate favourable safety and efficacy profile of Roche’s Hemlibra in people with moderate or mild haemophilia A (GlobeNewswire)
11.12.21	Roche presents pivotal data at ASH 2021 for novel cancer immunotherapy mosunetuzumab (GlobeNewswire)
10.12.21	New data from the phase II CITYSCAPE trial show encouraging results with Roche’s novel anti-TIGIT tiragolumab plus Tecentriq (GlobeNewswire)
07.12.21	Actemra/RoActemra approved by the European Commission to treat patients with severe COVID-19 (GlobeNewswire)
06.12.21	Roche completed the repurchase of Roche shares from Novartis (GlobeNewswire)
06.12.21	Roche hat Rückkauf der Roche-Aktien von Novartis vollzogen (GlobeNewswire)
06.12.21	CHMP recommends EU approval of Actemra/RoActemra to treat patients with severe COVID-19 (GlobeNewswire)
06.12.21	Roche to launch SARS-CoV-2 & Flu A/B Rapid Antigen Test in countries accepting the CE Mark to enable rapid differentiation of viral respiratory infections (GlobeNewswire)
03.12.21	Änderungen im Verwaltungsrat von Roche (GlobeNewswire)
03.12.21	Changes in the Board of Directors (GlobeNewswire)
03.12.21	Roche has rapidly developed additional testing options to differentiate mutations in the Omicron SARS-CoV-2 variant (GlobeNewswire)
01.12.21	Roche completes purchase agreement with long-term partner TIB Molbiol to expand PCR-test portfolio in the fight against new infectious diseases (GlobeNewswire)
26.11.21	Roche Extraordinary General Meeting 2021 (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	296.30	1.20 %	K V
Alcon	76.02	0.34 %	K V
ABB	48.88	0.31 %	K V
Givaudan	3’918.00	0.28 %	K V
Lonza Grp	529.60	0.27 %	K V
Nestle	73.64	-0.75 %	K V
Geberit	511.80	-0.93 %	K V
Holcim	86.10	-1.01 %	K V
Zurich Insur Gr	531.60	-1.23 %	K V
Sika	212.50	-2.79 %	K V

mehr

15:58		Zurückhaltung in Europa: Euro STOXX 50 präsentiert sich schwächer
15:58		Börse Frankfurt: So steht der LUS-DAX am Nachmittag
15:58		Börse Frankfurt: DAX präsentiert sich nachmittags leichter
15:58		Anleger in London halten sich zurück: So bewegt sich der FTSE 100 aktuell
15:58		SPI-Handel aktuell: SPI verliert
15:58		Handel in Zürich: SMI verbucht Verluste
13:22		GSK-Aktie verliert: GSK erreicht Fortschritte bei Eierstockkrebs-Therapie
13:13		Wechsel bei Sanofi: Ex-Morphosys-Chef Kress tritt in den Verwaltungsrat ein -Sanofi-Aktie tiefer

15:58

Zurückhaltung in Europa: Euro STOXX 50 präsentiert sich schwächer

15:58

Börse Frankfurt: So steht der LUS-DAX am Nachmittag

15:58

Börse Frankfurt: DAX präsentiert sich nachmittags leichter

15:58

Anleger in London halten sich zurück: So bewegt sich der FTSE 100 aktuell

15:58

SPI-Handel aktuell: SPI verliert

15:58

Handel in Zürich: SMI verbucht Verluste